JNJJanssen Research & Development, LLCRunning, no new patients
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 864 (final count)
- Started
- Oct 13, 2022
- Main results expected
- Jul 30, 2027
- Fully finished
- May 25, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Up to 6 years 6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05455320 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC